COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view

ABSTRACT: Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors, or monoclonal antibodies until disease progression. Continuous therapy in combination with the underlying disease frequently results in severe humoral and cellular immunodeficiency, which often...

Descripción completa

Detalles Bibliográficos
Autores principales: von Metzler, Ivana, Campe, Julia, Huenecke, Sabine, Raab, Marc S., Goldschmidt, Hartmut, Schubert, Ralf, Rabenau, Holger F., Ciesek, Sandra, Serve, Hubert, Ullrich, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520766/
https://www.ncbi.nlm.nih.gov/pubmed/34657968
http://dx.doi.org/10.1007/s00109-021-02114-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520766/
https://www.ncbi.nlm.nih.gov/pubmed/34657968
http://dx.doi.org/10.1007/s00109-021-02114-x

Ejemplares similares